CBM - Cambrex Corporation

NYSE - NYSE Delayed Price. Currency in USD
38.19
-1.07 (-2.73%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close39.26
Open38.95
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range38.14 - 39.14
52 Week Range33.80 - 69.43
Volume390,176
Avg. Volume430,486
Market Cap1.285B
Beta (3Y Monthly)2.31
PE Ratio (TTM)13.90
EPS (TTM)2.75
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-05-04
1y Target Est45.40
Trade prices are not sourced from all markets
  • Markit5 days ago

    See what the IHS Markit Score report has to say about Cambrex Corp.

    Cambrex Corp NYSE:CBMView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is contracting Bearish sentimentShort interest | NeutralShort interest is moderately high for CBM with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CBM had net inflows of $3.46 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers’ Index (PMI) data, output in the Basic Materialsis falling. The rate of decline is significant relative to the trend shown over the past year. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire10 days ago

    Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan

    Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m2 research and development laboratory at its site in Paullo, Milan, Italy. In addition, Cambrex has installed a new 12,000 liter reactor into one of its cGMP manufacturing facilities at the site. The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems, which have now been qualified and validated.

  • Do You Like Cambrex Corporation (NYSE:CBM) At This P/E Ratio?
    Simply Wall St.11 days ago

    Do You Like Cambrex Corporation (NYSE:CBM) At This P/E Ratio?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll look at Cambrex Corporation's (NYSE:CBM) P/E ratio and reflect onRead More...

  • Should Value Investors Pick Cambrex Corporation (CBM) Stock?
    Zacks12 days ago

    Should Value Investors Pick Cambrex Corporation (CBM) Stock?

    Is Cambrex Corporation (CBM) a great pick from the value investor's perspective right now? Read on to know more.

  • 3 Top Biotech Stocks to Buy in February
    Motley Foollast month

    3 Top Biotech Stocks to Buy in February

    Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.

  • CBM Missed Earnings by Over 90%
    InvestorPlacelast month

    CBM Missed Earnings by Over 90%

    To receive further updates on this Cambrex Corporation (NYSE:CBM) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of Power Options Weekly today.This morning I'm recommending a bearish trade on Cambrex Corporation (NYSE:CBM), a life sciences company.While my indicators are giving bullish readings again this week, they dipped briefly into neutral territory this week as the S&P 500 struggled to clear its 200-day moving average. The rally from the late-December bottom remains intact, although we did get some economic news on Thursday that was somewhat concerning.InvestorPlace - Stock Market News, Stock Advice & Trading TipsRetail sales dropped a seasonally adjusted 1.2% in December, which was the largest monthly drop since 2009. December is typically one of the stronger months for retail sales, as a lot of consumers do their holiday shopping that month, so this reading came as a surprise to Wall Street.Though I remain bullish in the near term, I am recommending a defensive position this morning in case the market makes a move to the downside. CBM missed earnings this week, and it has exposure in Europe, so I decided it would be a good downside play. Europe is StrugglingThe economic situation in Europe is not good at all. Their central bankers are all out of options for stimulating the region's economies, and that weakness has the potential to creep over into our markets eventually.Two of the three subsidiaries that own CBM's manufacturing facilities are located in Europe. CBM also has research and development facilities throughout Europe. If we do start to see Europe's economic issues affect our market, it will start with companies like CBM. No Support Above $30CBM reported earnings on Feb. 13, before market open, and it missed earnings estimates by over 90%. The stock dropped below support at the $36 level, and yesterday it dropped even further.Daily Chart of Cambrex Corporation (CBM) -- Chart Source: TradingViewCBM set a new 52-week low this week, and its next support level -- from early 2017 -- is at $30. The fundamental picture looks bad, and CBM doesn't have the technical support to keep the stock from falling further. That's why I'm recommending a bearish play this morning.Buy to open the Cambrex Corporation (CBM) April 18th $30 Puts (CBM190418P00030000) at $0.75 or lower. Note: The Good Friday holiday falls on April 19th, 2019. Because U.S. markets will be closed that day, April monthly options will expire the day before, on April 18th, 2019.Follow our Facebook page to receive each Trade of the Day direct to your News Feed -- and join the conversation.InvestorPlace advisor Ken Trester brings you Power Options Weekly, which delivers 5 new options trades and his latest trading advice to you each Friday. Trester has been trading options since the first exchanges opened in 1973 with a winning streak that goes back to 1984 with money-doubling average annual profits since 1990.Compare Brokers The post CBM Missed Earnings by Over 90% appeared first on InvestorPlace.

  • Cambrex Corp (CBM) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Cambrex Corp (CBM) Q4 2018 Earnings Conference Call Transcript

    CBM earnings call for the period ending December 31, 2018.

  • Why Cambrex Corporation Is Tanking Today
    Motley Foollast month

    Why Cambrex Corporation Is Tanking Today

    Shares dropped after the company reported mixed earnings.

  • Cambrex (CBM) Surpasses Q4 Earnings Estimates
    Zackslast month

    Cambrex (CBM) Surpasses Q4 Earnings Estimates

    Cambrex (CBM) delivered earnings and revenue surprises of 2.86% and -15.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Cambrex: 4Q Earnings Snapshot

    On a per-share basis, the East Rutherford, New Jersey-based company said it had profit of 4 cents. Earnings, adjusted for non-recurring costs and stock option expense, came to $1.44 per share. The results ...

  • GlobeNewswirelast month

    Cambrex Reports Fourth Quarter and Full Year 2018 Financial Results

    - Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Conference call at 8:30 a.m. ET on February 13, 2019 -.

  • Cambrex (CBM) Upgraded to Buy: Here's What You Should Know
    Zackslast month

    Cambrex (CBM) Upgraded to Buy: Here's What You Should Know

    Cambrex (CBM) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswirelast month

    Cambrex to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019

    EAST RUTHERFORD, N.J., Feb. 08, 2019 -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients.

  • CBM or ILMN: Which Is the Better Value Stock Right Now?
    Zacks2 months ago

    CBM or ILMN: Which Is the Better Value Stock Right Now?

    CBM vs. ILMN: Which Stock Is the Better Value Option?

  • Is Cambrex (CBM) a Great Value Stock Right Now?
    Zacks2 months ago

    Is Cambrex (CBM) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • CBM or ALKS: Which Is the Better Value Stock Right Now?
    Zacks2 months ago

    CBM or ALKS: Which Is the Better Value Stock Right Now?

    CBM vs. ALKS: Which Stock Is the Better Value Option?

  • Have Insiders Been Selling Cambrex Corporation (NYSE:CBM) Shares?
    Simply Wall St.2 months ago

    Have Insiders Been Selling Cambrex Corporation (NYSE:CBM) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • GlobeNewswire3 months ago

    New Research Coverage Highlights Twenty-First Century Fox, Hill-Rom, Amphenol, Imperva, Maximus, and Cambrex — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Cambrex Completes Acquisition of Avista Pharma Solutions

    Cambrex Corporation (CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it has completed the acquisition of Avista Pharma Solutions (“Avista”), a contract development, manufacturing, and testing organization, from Ampersand Capital Partners. The transaction, announced on November 20, 2018, strengthens Cambrex’s position as the leading, fully integrated small molecule contract development and manufacturing organization (CDMO) across the entire drug lifecycle.

  • Hedge Funds Are Crazy About Cambrex Corporation (CBM)
    Insider Monkey3 months ago

    Hedge Funds Are Crazy About Cambrex Corporation (CBM)

    Is Cambrex Corporation (NYSE:CBM) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]